Condoliase
| Clinical data | |
|---|---|
| Trade names | Hernicore |
| Other names | Chondroitinase ABC; SI-6603 |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| ECHA InfoCard | 100.029.785  |
| Chemical and physical data | |
| Formula | C5039H7770N1360O1525S22 |
| Molar mass | 112508.90 g·mol−1 |
Condoliase (Hernicore) is a biopharmaceutical for the treatment of lumbar disc herniation. It is an enzyme that degrades glycosaminoglycans.[1][2][3]
Condoliase is derived from the enzyme from the bacteria Proteus vulgaris.[3]
It was approved for use in Japan in 2018.[4]
References[]
- ^ Chiba K, Matsuyama Y, Toyama Y (2014). "Efficacy and Safety of Condoliase in Patients with Lumbar Disc Herniation: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial". The Spine Journal. 14 (11): S30. doi:10.1016/j.spinee.2014.08.081.
- ^ Matsuyama Y, Chiba K, Iwata H, Seo T, Toyama Y (May 2018). "A multicenter, randomized, double-blind, dose-finding study of condoliase in patients with lumbar disc herniation". Journal of Neurosurgery. Spine. 28 (5): 499–511. doi:10.3171/2017.7.SPINE161327. PMID 29424676.
- ^ a b Chiba K, Matsuyama Y, Seo T, Toyama Y (August 2018). "Condoliase for the Treatment of Lumbar Disc Herniation: A Randomized Controlled Trial". Spine. 43 (15): E869–E876. doi:10.1097/BRS.0000000000002528. PMID 29257028. S2CID 24111394.
- ^ Seikagaku, Kaken Pharmaceutical (March 23, 2018). "Seikagaku Announces New Drug Application Approval of HERNICORE® 1.25 Units for Intradiscal Injection in Japan, Indicated for Treatment of Lumbar Disc Herniation" (Press release). Evaluate Group.
Categories:
- Biopharmaceuticals